Abstract: A layered patch for inserting and fixating an intravenous (IV) device, the patch including a first layer configured to adhere to a patient's skin, the first layer having a slot configured to expose a blood vessel of the patient, wherein the slot is sized and shaped to allow essentially unhindered access of the IV device to the exposed blood vessel, and wherein lateral edges of the slot include a bulged structure configured to prevent/inhibit lateral movement of the exposed blood vessel; and a second layer configured to be placed over and/or adhere to the first layer, wherein the first and second layers are attached one to another at a first end thereof.

Abstract: Propargylamine, propargylamine derivatives N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for administration to a subject at high risk for or suffering from acute renal failure (ARF).

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

Abstract: A container for storing a plurality of bottles. The container comprises an inflatable assembly having a plurality of holes with bulging walls. Each one of the holes is configured to encircle at least one of the plurality of bottles.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or attenuation of anthracycline-induced cardiotoxicity.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of renal failure.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.

Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders and diseases.

Abstract: The invention provides a method for determining the effects of an agent on repolarization of cells in vitro, comprising stimulating the cells with an energy source and under conditions sufficient and for a time sufficient to depolarize the cells, measuring the QT interval of the electrical signals output by the cells in response to the stimulating step, contacting the cells with an agent, re-stimulating the cells with the same energy source and under the same conditions as the first stimulating step and for a time sufficient to depolarize the cells, measuring the QT interval of the electrical signals output by the cells in response to the second stimulating step, and comparing the results of the measuring taken after the first and second stimulating steps to determine whether the agent affects repolarization of cells. The present invention also provides a method for determining the effects of an agent on conduction of cells in vitro.

Abstract: The invention discloses anti-tumor activity in the sera of certain reptiles, more particularly in the serum of alligators or crocodiles. The active principle resides in one or more serum proteins or polypeptides that inhibit the growth of mammalian tumor cells in culture while being practically devoid of such inhibitory activity toward normal cells in culture. The active fractions obtained from the sera show no overt toxicity in healthy mammals, and this novel anti-tumor agent may therefore be used for the prevention, investigation, treatment or diagnosis of neoplasms.

Abstract: The present invention provides compositions useful as antimicrobial agents which include reptilian hemoglobin, the &agr; and &bgr; chains of hemoglobin free of heme, fragments of said proteins or polypeptide fragments thereof and combinations thereof. The compositions exert antimicrobial activity against both bacteria and fungi that is comparable to known antimicrobial peptides from human neutrophils, cathepsin G and azurocidin. Sensitive organisms include Gram-negative bacteria such as Escherichia coli and Pseudomonas aerioginosa, and the fungus Candida albicans. Methods for preparing the compositions also are provided.